Clinical trials: COVID-19, open to volunteers
Post-Coronavirus Disease 19
Natural History of Post-Coronavirus Disease 19 Convalescence at the National Institutes of Health
Background: People who get COVID-19 have a wide range of symptoms. They also recover from COVID-19 in different ways. In this study, researchers will use survey data to describe the different ways people experience and recover…
- Trial name
- NCT04573062
- Where
- United States
- Volunteers
- 1,590 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Mental Health
Women s Health Awareness Community Resiliency, Environmental Action and Collaborations for Health (REACH)
Background: Inequalities in COVID-19 infection, hospitalization, and death in under-studied, under-represented, and under-reported groups of people are severe.
- Trial name
- NCT04983251
- Where
- United States
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- National Institute of Environmental Health Sciences (NIEHS)
Long COVID
DAOIB for the Treatment of Brain Fog
This is a 24-week open trial. We will enroll long-COVID patients with cognitive impairments. All patients will receive DAOIB for 24 weeks.
- Trial name
- NCT05764538
- Testing
- DAOIB
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- Chang Gung Memorial Hospital
Post-Acute COVID-19 Syndrome
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Background: SARS-CoV-2 is the virus that causes COVID-19. Some people who recover from an acute COVID-19 infection may continue to have symptoms that persist for months or years.
- Trial name
- NCT07388550
- Testing
- Keytruda
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
COVID-19
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
This phase 1 randomized, open-label, dose-escalation clinical trial evaluates the safety and immunogenicity of OCU500, a ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine, in healthy adults aged 18-64 who previously completed a…
- Trial name
- NCT07536308
- Testing
- OCU500
- Where
- 6 sites in United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Respiratory Viral Infections, Influenza
Effect of MxA Guidance on Antiviral Treatment in Respiratory Viral Infections
The goal of this clinical trial is to evaluate the effects of myxovirus resistance protein A (MxA)-guided antiviral treatment on treatment duration and adverse outcomes in adults hospitalized with influenza or COVID-19, compared…
- Conditions
- Respiratory Viral Infections, Influenza, SARS CoV 2 Infection
- Trial name
- NCT07892872
- Testing
- Baseline MxA testing, Serial MxA testing, MxA result feedback and antiviral treatment recommendations
- Where
- China
- Volunteers
- 618 people
- Sponsor
- Capital Medical University
Long COVID, Post COVID-19 Condition
Effect of Hi-OxSR for the Treatment of Post COVID Condition
The RECLAIM study platform will be used to explore whether the use of the Hi-OxSR device improves the symptoms of post covid cognitive dysfunction.
- Conditions
- Long COVID, Post COVID-19 Condition, Post Acute Sequelae of COVID-19
- Trial name
- RECLAIM-HiOxSR (NCT06928506)
- Testing
- Hi-OxSR device, Hi-Ox device
- Where
- 3 sites in Canada
- Volunteers
- 120 people
- Sponsor
- University Health Network, Toronto
Immunization, Healthy Volunteers
Study of a Combination SARS-CoV-2 Recombinant Spike and High-Dose Inactivated Influenza Vaccine With Matrix-M Adjuvant in Adult Participants 60 Years of Age and Older
The purpose of this study is to assess the safety and immunogenicity of IIV-HD + NVXC19 vaccine compared to seasonal influenza vaccine (IIV-HD) and COVID-19 vaccine, adjuvanted (NVXC19) coadministered in adult participants 60…
- Conditions
- Immunization, Healthy Volunteers, COVID-19 Immunization, Influenza Immunization
- Trial name
- NCT07890454
- Testing
- IIV-HD (standalone), NVXC19 (EU licensed, standalone), IIV-HD + NVXC19 combination
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- Sanofi
Covid19 Pneumonia
Prevention of COVID-19 Infection to Severe Pneumonia or ARDS
A trial of EC-18 in patients with mild/moderate pneumonia due to COVID-19
- Trial name
- NCT04569227
- Testing
- EC-18
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Enzychem Lifesciences Corporation
Post-Concussion Syndrome, COVID Long-Haul
Percutaneous Electrical Nerve Field Stimulation (PENFS) in Patients With Post Concussion Syndrome (PCS)
The purpose of this study is to test the effect of Auricular Percutaneous Electrical Nerve Field Stimulation (a Neurostim device) on children with pain and Post Concussion symptoms.
- Conditions
- Post-Concussion Syndrome, COVID Long-Haul, COVID-19
- Trial name
- NCT04978571
- Testing
- percutaneous electrical nerve-field stimulation, PENFS, percutaneous electrical nerve-field stimulation, PENFS (COVID active device)
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- Children's Hospital of Orange County
Coronavirus Disease (COVID-19)
A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)
Researchers are looking for other ways to prevent severe illness from COVID-19. COVID-19 is a virus that most often causes mild flu or cold-like symptoms.
- Trial name
- MOVe-NOW (NCT06667700)
- Testing
- Molnupiravir
- Where
- 227 sites in United States, Argentina and 22 more
- Volunteers
- 3,082 people
- Sponsor
- Merck Sharp & Dohme LLC
Vaccination Coverage Among Pregnant Women
Assessment of the Acceptability of, and Factors Associated With, Recommended Vaccinations During Pregnancy in Maternity Units in the Ile-de-France Region
The objective of this study is to assess vaccination coverage (VC) for vaccines recommended during pregnancy (pertussis, COVID-19, seasonal influenza, and respiratory syncytial virus [RSV] infection), their acceptability, and the…
- Trial name
- RECOVAX (NCT07882186)
- Where
- 16 sites in France
- Volunteers
- 1,605 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
COVID-19, Immunodeficiency
OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Randomized Factorial Controlled Strategy Trial
The overall purpose of the trial is to evaluate the efficacy and safety of possible combination antiviral therapy DAA (remdesivir + nirmatrelvir/r)∞ versus the reference monotherapy (nirmatrelvir/r alone) and to assess the…
- Trial name
- OPTICOV (NCT05587894)
- Testing
- Paxlovid 5 days, Paxlovid 10 days, Veklury
- Where
- 18 sites in France, Italy and 1 more
- Volunteers
- 256 people
- Sponsor
- ANRS, Emerging Infectious Diseases
MIS-C Associated With COVID-19
Genetic Basis of SARS-CoV-2 Infection-Associated Multisystem Inflammatory Syndrome in Children (MIS-C)
The project aims to investigate the molecular basis of pediatric inflammatory conditions associated with COVID-19 identified by the IDEA network, with the objectives of characterizing their genetic background, pathophysiology…
- Trial name
- MIS-C IDEA (NCT07881068)
- Where
- 3 sites in Italy
- Volunteers
- 150 people
- Sponsor
- Istituto Giannina Gaslini
Healthy Participants
Study of S-892216 Long-acting Injectable (LAI) in Healthy Adult Participants
The purpose of this study is to investigate the safety, tolerability, and pharmacokinetics (PK) of single- and multiple-dose administration of S-892216-LAI in healthy adults.
- Trial name
- NCT07093580
- Testing
- S-892216-LAI
- Where
- 3 sites in United States
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Shionogi
Long COVID, Post COVID-19 Condition
Taurine Supplementation in Adolescents With Post-COVID Condition
The COVID-19 pandemic has swept across the globe, affecting millions of individuals with varying degrees of severity. While many individuals recover from the acute phase of the infection, a significant proportion continue to…
- Conditions
- Long COVID, Post COVID-19 Condition, PASC Post Acute Sequelae of COVID 19
- Trial name
- TaurineLCPeds (NCT07682402)
- Testing
- Taurine
- Volunteers
- 30 people
- Sponsor
- University of Alberta
COVID -19
A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine
This phase 1 clinical trial will evaluate the safety, reactogenicity, and immunogenicity of RVX-sCPD9, given Intranasally (IN), as a booster dose to previously vaccinated healthy adults.
- Trial name
- NCT07703475
- Testing
- RVX-sCPD9
- Where
- 4 sites in United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19, Long COVID
Effectiveness of Transcranial Direct Current in Patients With Persistent COVID-19 With Headaches and Chronic Pain.
This study aims to verify the efficacy/effectiveness of treatment with transcranial direct current stimulation (TDCS) in patients with Long Covid who experience headaches, migraines, and chronic pain, such as arthralgia and…
- Conditions
- COVID-19, Long COVID, Long Covid19, SARS CoV 2 Infection
- Trial name
- NCT05780450
- Testing
- Transcranial Direct Current Therapy (tDCS)
- Where
- 2 sites in Spain
- Volunteers
- 87 people
- Sponsor
- Fundación Universidad Católica de Valencia San Vicente Mártir
ME/CFS, Long COVID
LIFT: Life Improvement Trial
The LIFT will be conducted at Brigham and Women's Hospital (BWH) of Harvard Medical School, focusing on the effect of Pyridostigmine (Mestinon) and Low-Dose Naltrexone (LDN) in subjects aged 18-70 meeting the Canadian consensus…
- Conditions
- ME/CFS, Long COVID, PASC
- Trial name
- LIFT (NCT06366724)
- Testing
- Pyridostigmine, Low-Dose Naltrexone
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- Brigham and Women's Hospital
COVID-19 SARS-CoV-2 Infection
A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease
The purpose of the study is to evaluate whether ibuzatrelvir is effective and safe in adults and adolescents with COVID-19 who do not need to be in the hospital but who are at high risk for progression to severe disease.
- Trial name
- NCT06679140
- Testing
- ibuzatrelvir
- Where
- 256 sites in United States, Argentina and 17 more
- Volunteers
- 2,330 people
- Sponsor
- Pfizer